| 1 |
2021 |
D. Lorusso, G. Daniele. First line ovarian cancer treatment: Scanning the horizon, Critical Reviews in Oncology/Hematology. 2021; 160: 103297103297.
https://doi.org/10.1016/j.critrevonc.2021.103297 |
| 2 |
2024 |
Toru Ogura, Chihiro Shiraishi. Comparison of adverse events of poly adenosine diphosphate ribose polymerase inhibitors in patients with ovarian cancer using the United States Food and Drug Administration Adverse Event Reporting System, Expert Opinion on Drug Safety. 2024; 1.
https://doi.org/10.1080/14740338.2024.2418333 |
| 3 |
2020 |
Domenica Lorusso, Valentina Ceni, Margherita Muratore, Vanda Salutari, Camilla Nero, Antonella Pietragalla, Francesca Ciccarone, Vittoria Carbone, Gennaro Daniele, Giovanni Scambia. Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer, Expert Opinion on Emerging Drugs. 2020; 25: 445.
https://doi.org/10.1080/14728214.2020.1836155 |
| 4 |
2024 |
Ricardo G. Teixeira, Alessia Stefanelli, Adhan Pilon, Rebecca Warmers, Xavier Fontrodona, Isabel Romero, Paulo J. Costa, Maria J. Villa de Brito, Xenia Hudec, Christine Pirker, Sebastian Türck, Alexandra M. M. Antunes, Christian R. Kowol, Ingo Ott, Anamaria Brozovic, Andy Sombke, Margret Eckhard, Ana Isabel Tomaz, Petra Heffeter, Andreia Valente. Paraptotic Cell Death as an Unprecedented Mode of Action Observed for New Bipyridine-Silver(I) Compounds Bearing Phosphane Coligands, Journal of Medicinal Chemistry. 2024; 67: 6081.
https://doi.org/10.1021/acs.jmedchem.3c01036 |
